Gen Eng News: More CO Action!

If memory serves me correctly I have waxed on in the past about my affinity for Genetic Engineering News and often highlighted the journal when a Colorado company ended up in print there. Well the love story continues with the 15 November issue where Carol Potera composed a three-page treatise on the Colorado Science + Technology Park @ Fitzsimons and beyond.

A few companies highlighted include 1) MBC Pharma who is focused upon bone disease such as osteoporosis and cancer metastases, patients who die from breast, prostate or lung cancer have bone metastases and, presentation with bone metastases is correlated with shorter survival 2) MycoLogics, a company near and dear to my heart that is among other pursuits focused upon developing prophylactic and therapeutic approaches to Leishmaniasis, a disease where 350 million people in developing countries are at risk. 3) Caveo Therapeutics who is working on the discovery and development of biopharmaceuticals to treat and cure hematalogic conditions by inhibiting certain families of tyrosine kinases 4) ARCA Discovery who is developing genetically targeted therapies for heart failure and other cardiovascular disease, an NDA for bucindolol is expected to be filed shortly, and finally 5) Lohocla Research is a discovery and development company specializing in addiction, neurological disorders and related biomarkers for companion diagnostics.

You can read the article (here).

If you enjoyed this post get free email updates (here).

Caveo Therapeutics: At Lead Optimization

Caveo Therapeutics (Aurora, CO) is developing a pipeline of innovative biopharmaceutical products for the treatment and cure of hematologic malignancies as well as metastatic disease. Lead candidates have been identified following in vivo preclinical studies and are currently undergoing lead optimization. The company’s technologies identify biological inhibitors that block receptors on various cell types against excessive or inappropriate activation which can lead to malignancy. The initial products are designed to inhibit the TAM, Tyro-3, Axl and Mer family of receptor tyrosine kinases, which participate in the blood clotting cascade and are implicated in many cancers including refractory leukemias and lymphomas.

In addition, Caveo Therapeutics has available two highly specific monoclonal antibodies to the Mer receptor tyrosine kinase: CVO-311 and CVO-312 to detect Mer expressed in human tissue, cell lines and the extracellular domain shed into plasma by metalloprotease cleavage.

Order antibodies (here).

If you enjoyed this post get free email updates (here).